跳至主要内容
临床试验/NCT06501339
NCT06501339尚未招募4 期

Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole on Psychopathology and Cerebral Perfusion in Clozapine-resistant Schizophrenia: a Randomized, Double-blind Controlled Trial

All India Institute of Medical Sciences, Bhubaneswar0 个研究点目标入组 40 人开始时间: 2024年8月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
40
主要终点
Change in Positive And Negative Syndome Scale score

研究概览

简要总结

The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS. However, literature on the role of M-ECT in maintaining the therapeutic gains of acute ECT in CRS is lacking. The objective of the study is to compare the efficacy of M-ECT vs aripiprazole as an add-on to ongoing clozapine on the severity of symptom dimensions, cerebral perfusion, global functioning and cognitions in patients with CRS.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Patients clinically diagnosed with CRS (currently under clozapine)
  • Patients aged 18-60 years of either sex.
  • LAR giving voluntary written consent for participation in the study

排除标准

  • Patient already on ECT or aripiprazole.
  • History of psychoactive substance abuse or dependence.
  • Co-morbid psychiatric, major medical or neurological disorders.
  • History of organicity or significant head injury.
  • Pacemaker or metal in any body part, excluding the mouth. Pregnant and breastfeeding females.

研究组 & 干预措施

Maintenance ECT

Experimental

干预措施: maintenance ECT (Procedure)

Aripiprazole

Active Comparator

干预措施: Aripiprazole tablet (Drug)

结局指标

主要结局

Change in Positive And Negative Syndome Scale score

时间窗: Baseline, 6 weeks, 12 weeks, 24 weeks

Change from baseline in Total, Positive, negative and general scores with treatment. Minimum value: 30; maximum value: 210. Higher score means worsening of symptoms

次要结局

  • Change in regional cerebral blood flow by the SPECT-CT brain(Baseline, 24 weeks)
  • change in the Monteal Cognitive Assessment scores(Baseline,6 weeks, 12 weeks, 24 weeks)
  • change in the Global Assessment of Functioning scores(Baseline, 6 weeks, 12 weeks, 24 weeks)
  • Safety evaluation(Baseline,6 weeks, 12 weeks, 24 weeks)

研究者

发起方
All India Institute of Medical Sciences, Bhubaneswar
申办方类型
Other
责任方
Principal Investigator
主要研究者

BISWA RANJAN MISHRA

Additional Professor, Psychiatry

All India Institute of Medical Sciences, Bhubaneswar

相似试验